Evaluation of 1, 2:5, 6 Dianhydrogalactitol (NSC-132313) in Patients with Advanced Cancer

Phase II evaluation of galactitol in head and neck cancer: A Southwest Oncology Group study.

CD Haas;D Lehane;R Bottomley Med & Ped Oncol 11:281-283

Phase II trial of Dianhydrogalactitol (NSC-132313) in advanced renal carcinoma. A Southwest Oncology Group study.

V Ratanatharathorn;LH Baker;L Balducci;RW Talley;B Hoogstraten Cancer Treat Rep 66:1231-1232

Phase II evaluation of Dianhydrogalactitol in lung cancer: A Southwest Oncology Group study.

CD Haas;LH Baker;T Thigpen Cancer Treat Rep 65:115-117

Phase II trial of Dianhydrogalactitol in metastatic malignant melanoma. A Southwest Oncology Group study.

JT Thigpen;M Al-Sarraf;JS Hewlett Cancer Treat Rep 63(4):525-528

Phase II trial of Dianhydrogalactitol in advanced soft tissue and bony sarcomas. A Southwest Oncology Group study.

JT Thigpen;MK Samson Cancer Treat Rep 63(4):553-555

1,2:5,6 dianhydrogalactitol in advanced breast cancer

B Hoogstraten;RM O'Bryan;S Jones Cancer Treat Rep 62(5):841-842

Phase II evaluation of dianhydrogalactitoal (DAG) in treatment of advanced sarcoma and malignant melanoma.

T Thigpen;FS Morrison;LH Baker AACR, #958